enGene Therapeutics Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
enGene reported Q3 2026 net loss of $32.5M ($0.47/share) on operating expenses of $34.0M, with cash position of $266.3M as of July 31, 2026. Lead program detalimogene achieved 54% complete response rate in pivotal LEGEND Cohort 1 (125 BCG-unresponsive NMIBC patients); company plans pre-BLA meeting with FDA and BLA submission initiation in Q4 2026. Board chair transition completed (Michael Heffernan succeeded Richard Glickman after 14 years). Surfactant combination cohort safety run-in cleared; preclinical data shows 9-10 fold increase in IL-12 expression.
Why this rating
Regulatory milestone (BLA filing path) on-track for lead asset in 173M company; strong cash runway ($266M) supports execution; 54% CR rate material but preliminary. Clinical progress vs. size is significant.
Tradability signal
NO TRADE
No trade: price $0.23 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.23 | +10 min · unknown $0.23 ▲ 0.00% | +30 min · unknown $0.23 ▲ 0.00% | +1 hr · unknown $0.23 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.